Webinar: Understanding Follicular Lymphoma Clinical Trials
View our webinar focused on sharing experiences and improving understanding of clinical trials.
$2.25 Million to Research United to CURE Follicular Lymphoma
This strategic alliance with LLS and IFLI will further accelerate pioneering research and help cure follicular lymphoma through our Research United to CURE FL program.
Latest follicular lymphoma research updates from recent scientific conferences
The team updates from recent scientific conferences on the latest research in follicular lymphoma, from cutting-edge therapies to genetic insights.
South West Coast 50 Ultra Challenge
Challenge yourself with the South West Coast 50 Ultra Challenge on Saturday 3rd August.
What is the potential for minimal residual disease in follicular lymphoma treatment?
Minimal/measurable residual disease refers to the small number of cancer cells remaining in the body after treatment.
Immunotherapy: Can we make better CAR-Ts and bispecific antibodies?
How do we improve immunotherapy treatments to ensure long-lasting effectiveness, fewer side effects, and ensure they are accessible?
Immunotherapy: A breakthrough in follicular lymphoma treatmentÂ
Dr Mitchell Smith, FLF CMO, explains Immunotherapy and what it means for people living with follicular lymphoma in terms of treatment.
Latest breakthroughs & updates on FL, from ASH 2023 Annual MeetingÂ
Dr Mitchell Smith, FLF CMO, reports on the most exciting presentations at ASH 2023 including fundamental scientific discoveries and ongoing clinic trials.
Over £500,000 raised at our inaugural Invisible Incurable Gala Dinner
We are thrilled to announce that this remarkable event saw us raise an astounding £500,000 to further our mission of finding a cure for follicular lymphoma.
FLF to attend the 65th ASH Annual Meeting
The FLF will be attending the prestigious 65th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego this December.